A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Conditions:   Epstein-Barr Virus (EBV)-Associated Diseases;   EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (PID LPD);   EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (AID LPD);   EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous Syste m (CNS PTLD);   EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD);   Solid Organ Transplant Complications;   Lymphoproliferative Disorders;   Allogeneic Hematopoietic Cell Transplant;   Stem Cell Transplant Complications;   EBV+ Sarcomas;   Leiomyosarcoma;   Chronic Ac tive Epstein-Barr Virus (CAEBV);   Chronic Active Epstein-Barr Virus With Hemophagocytic Lymphohistiocytosis (HLH);   Lymphohistiocytosis, Hemophagocytic Intervention:   Biological: Tabelecleucel Sponsor:   Atara Biotherapeutics Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials